Metabolic Surgery for Atrial Fibrillation Elimination

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation. The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.

NCT Number	NCT07027969
Lead Sponsor	Ali Aminian Collaborators: Ethicon, Inc., iRhythm Technologies, Inc.
Conditions	Atrial Fibrillation, Obesity and Obesity-related Medical Conditions
Enrollment	100 participants
Start Date	2026-11-01
Primary Completion	2029-12-31 (estimated)
Study Completion	2030-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-17